Daiichi Sankyo’s Herceptin Biosimilar Might Hit Market as Early as November, Breast Cancer Use Also Eyed

Daiichi Sankyo’s Herceptin (trastuzumab) biosimilar, the company’s first follow-on biologic, might reach the market as early as November for the treatment of not only gastric cancer but also breast cancer, an indication dropped by a leading competitor approved earlier this...read more